POTASSIUM PHOSPHATES INJ 224 MG
POTASSIUM PHOSPHATE MONOBASIC : 224 MG POTASSIUM PHOSPHATE DIBASIC : 236 MG · DIN 01944878 · LYPHOMED, DIVISION OF FUJISAWA CANADA INC.
Health Canada status: CANCELLED POST MARKET
What is POTASSIUM PHOSPHATES INJ?
POTASSIUM PHOSPHATES INJ 224 MG contains POTASSIUM PHOSPHATE MONOBASIC : 224 MG POTASSIUM PHOSPHATE DIBASIC : 236 MG. It is listed in the Health Canada Drug Product Database under DIN 01944878, held by LYPHOMED, DIVISION OF FUJISAWA CANADA INC., supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 10-Sep-1996. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01944878 |
|---|---|
| Brand name | POTASSIUM PHOSPHATES INJ |
| Generic / active ingredient | POTASSIUM PHOSPHATE MONOBASIC : 224 MG POTASSIUM PHOSPHATE DIBASIC : 236 MG |
| Manufacturer | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. |
| Strength | 224 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05XA06 POTASSIUM PHOS INCL COMB W/0TH POT. SALTS |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 10-Sep-1996 |
| Original market date | 1984-12-31 00:00:00 |
Is POTASSIUM PHOS INCL COMB W/0TH POT. SALTS in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B05XA06 POTASSIUM PHOS INCL COMB W/0TH POT. SALTS. 3 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| POTASSIUM PHOSPHATE MONOBASIC INJECTION | 176 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00711306 |
| POTASSIUM PHOSPHATES | 236 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00804789 |
| POTASSIUM PHOSPHATES INJECTION, USP | 224 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02139545 |
| POTASSIUM PHOSPHATE INJ 3MMP/ML | 224 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00351539 |
Who else supplies POTASSIUM PHOS INCL COMB W/0TH POT. SALTS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. POTASSIUM PHOS INCL COMB W/0TH POT. SALTS appears in 158 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.